# Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma

> **NCT04051606** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT04051606
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-31
- **Primary completion:** 2024-03-20
- **Final completion:** 2024-03-20
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04051606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04051606, "Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04051606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*